Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

60.57
+0.21000.35%
Volume:136.00K
Turnover:8.22M
Market Cap:10.07B
PE:-17.41
High:60.99
Open:60.37
Low:60.27
Close:60.36
52wk High:86.74
52wk Low:49.13
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.52
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:22.89
PE(LYR):-25.44

Loading ...

Ionis Pharmaceuticals Cut to Peer Perform from Outperform by Wolfe Research

Dow Jones
·
Jul 16

Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data

TIPRANKS
·
Jul 16

Ionis Pharmaceuticals call volume above normal and directionally bullish

TIPRANKS
·
Jul 16

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 15

Press Release: Ionis to Hold Second Quarter 2026 Financial Results Webcast

Dow Jones
·
Jul 15

Ionis Pharmaceuticals Schedules Webcast on Second-quarter 2026 Results

Reuters
·
Jul 15

Ionis Partner Biogen Presents Phase 2 Celia Data at Aaic Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

THOMSON REUTERS
·
Jul 14

Ionis Pharmaceuticals is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 13

Ionis Doses First Patient in Phase 1-2 Trial of Ion337 for Dravet Syndrome

Reuters
·
Jul 13

Ionis Doses First Participant in Phase 1-2 Ascend Study of Ion337 in Dravet Syndrome

THOMSON REUTERS
·
Jul 13

RBC Cuts Price Target on Ionis Pharmaceuticals to $85 From $100, Keeps Outperform Rating

MT Newswires Live
·
Jul 13

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's?

Dow Jones
·
Jul 13

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

MT Newswires Live
·
Jul 11

Movement Alert|Ionis Pharmaceuticals Falls 6.04% in Regular Trading, Aftershock Continues from Phase 3 ATTR-CM Trial Failure

Market Focus
·
Jul 10

H.C. Wainwright trims Ionis price target, says trial failure reaction ‘overdone’

TIPRANKS
·
Jul 10

Ionis Pharmaceuticals Inc : H.c. Wainwright Cuts Target Price to $125 from $130

THOMSON REUTERS
·
Jul 10

Ionis Pharmaceuticals Reaffirms Fiscal 2026 Financial Guidance

MT Newswires Live
·
Jul 10

Ionis Pharmaceuticals Reaffirms 2026 Financial Guidance Outlook

TIPRANKS
·
Jul 10

Ionis Pharmaceuticals - Reaffirms Fy2026 Financial Guidance - SEC Filing

THOMSON REUTERS
·
Jul 10

Barclays Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jul 10